Enrollment completed in Ph 2 trial of spevatamig + chemo for the 1L metastatic pancreatic ductal adenocarcinoma
“This marks an important milestone in our mission to advance innovative therapies that help improve outcomes for patients with hard-to-treat cancers,” said Ming Wang, PhD, MBA, CEO of Phanes. “PDAC is the first cancer type we are targeting with spevatamig; there is more to come.”
Share:
More News
“With this financing, we are well positioned to complete IND-enabling studies and advance TAVST01 toward its planned IND submission, bringing us closer to delivering a scalable, readily available, and potentially transformative cell therapy for patients with solid tumors”, said Dr. Ivan Horak, Founder and Chief Executive Officer of Tikva Allocell.
“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and
We are proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics,” said Vinita Gupta, Chief Executive Officer, Lupin. “The strength of these assets, combined with Kaveri’s seasoned leadership team, positions us to accelerate the development of targeted oncology therapies with the goal of
Dr Jonathan Kwok, Co-Founder, President and Chief Medical Officer, Infinitopes, said, “Entering the clinic is a defining milestone for successful future medicines. For Infinitopes, VISTA represents the first clinical evaluation of our integrated approach that combines Precision Immunomics target discovery with proven viral vectors, to engineer precise, off-the-shelf therapies for